1394-P: Risk for Newly Diagnosed Type 2 Diabetes Mellitus after SARS-CoV-2 Infection among Korean Adults—A Nationwide Matched Cohort Study

Abstract

Background: There is growing evidence that coronavirus disease 2019 (COVID-19) can cause various extrapulmonary sequelae, including diabetes. However, it is unclear whether these effects persist even after 30 days from the date of diagnosis. We investigated the incidence of newly diagnosed type 2 diabetes mellitus (T2DM) during the post-acute phase of COVID-19. Methods: This cohort study used data from the Health Insurance Review and Assessment Service, a representative national healthcare database in Korea. We initially established a cohort of 348,180 people among those diagnosed with COVID-19 without a history of any diabetes between January 2020, and September 2021. Among people with neither a history of any diabetes nor a diagnosis of COVID-19, the control group consisted of sex- and age-matched people with the cohort. We assessed the hazard ratio (HR) of newly diagnosed T2DM in patients with COVID-19 compared to the control adjusted for age, sex, and presence of hypertension and dyslipidemia. Results: In the post-acute phase of COVID-19, patients with COVID-19 had an increased risk of newly diagnosed T2DM than those without COVID-19 (adjusted HR 1.30, 95% CI 1.27-1.33). The adjusted HRs of non-hospitalized, hospitalized, and intensive care unit-admitted patients were 1.14 (95% CI 1.08-1.19), 1.34 (95% CI 1.30-1.38), and 1.78 (95% CI 1.59-1.99), respectively. Conclusion: COVID-19 may increase the risk of developing T2DM beyond the acute period. The higher the severity of COVID-19 in the acute phase, the higher the risk of newly diagnosed T2DM. Therefore, T2DM should be included as a component for managing long COVID. Disclosure J.Choi: None. K.Song: None.